Muxava Tablets / Film-coated
Moxifloxacin
400mg
AL-TAQADDOM PHARMACEUTICAL INDUSTRIES
| Pack size | 5's Blister |
|---|---|
| Dispensing mode | POM |
| Source | JORDAN |
| Agent | PHARMALINK |
| Retail Price | 34.50 AED |
Available as:
Indications
Muxava Tablets / Film-coated is used for:
Community Acquired Pneumonia, Acute Bacterial Exacerbation of Chronic Bronchitis, Acute Bacterial Sinusitis, Complicated Intra-Abdominal Infection, Uncomplicated Skin and Skin Structure Infections, Complicated Skin and Skin Structure Infections, Typhoid Fever.
Adult Dose
Oral
The dose of Moxifloxacin is 400 mg once every 24 hours. The duration of therapy depends on the type of infection as described bellow
Acute Bacterial Sinusitis
400 mg is given once daily for 10 days.
Acute Bacterial Exacerbation of Chronic Bronchitis
400 mg is given once daily for 5 days.
Community Acquired Pneumonia
400 mg is given once daily for 7-14 days.
Uncomplicated Skin & Skin Structure infections
400 mg is given once daily for 7 days.
Complicated Skin & Skin Structure infections
400 mg is given once daily for 7-21 days.
Complicated Intra-Abdominal infections
400 mg is given once daily for 5-14 days.
Typhoid Fever
400 mg is given once daily for 10-14 days.
Child Dose
<18 years: Safety and efficacy not established
Renal Dose
Administration
May be taken with or without food.
Contra Indications
Known hypersensitivity to moxifloxacin, other quinolones. Patients w/ known prolongation of QT interval, uncorrected hypokalaemia, myasthenia gravis. Concurrent use of class Ia (e.g.quinidine, procainamide, class III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents).
Precautions
Maintain adequate fluid intake; Patient w/ previous tendon disorders (e.g. rheumatoid arthritis), significant bradycardia or acute myocardial ischaemia, heart failure w/ reduced LVEF, known history of symptomatic arrhythmias, known or suspected CNS disorders (e.g. severe cerebral arteriosclerosis, epilepsy) or other risk factors that predispose to seizures; diabetes. Kidney, heart or lung transplant recipients. Hepatic impairment. Pregnancy and lactation.
Patient Counselling This drug may cause dizziness and lightheadedness, if affected do not drive or operate machinery. Rest and refrain from doing strenuous physical activity as it may increase risk of tendon rupture. Avoid exposure to sunlight or artificial UV light (e.g. tanning beds, UVA/UVB treatment) and use protective measures (e.g. sunscreen, wear loose-fitting clothes) if staying outdoors is necessary during therapy. Monitoring Parameters Monitor WBC and signs of infection.
Pregnancy-Lactation
Pregnancy
There are no available human data establishing a drug associated risk; however, when moxifloxacin was administered to rats during pregnancy and throughout lactation at doses associated with maternal toxicity, decreased neonatal body weights, increased incidence of skeletal variations (rib and vertebra combined), and increased fetal loss were observed
Advise pregnant women of potential risk to fetus
Lactation
Not known if moxifloxacin is present in human milk
Based on animal studies in rats, moxifloxacin may be excreted in human milk
Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on the breastfed child from drug or from the underlying maternal condition
Interactions
Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine.
Potentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.
Adverse Effects
Side effects of Moxifloxacin :
1-10%
Nausea (7%), Diarrhea (6%), Dizziness (3%), Decreased amylase (2%), Decreased basophils, eosinophils, hemoglobin, prothrombin time, red blood cells, neutrophils (2%), Decreased serum glucose (2%), Increased serum chloride (2%), Increased serum ionized calcium (2%), Immune hypersensitivity reaction (0.1-2%), Prolonged QT interval (0.1-2%)
<1%
Acute renal failure, Agranulocytosis, Anaphylactoid reaction, Aplastic anemia, Extrinsic allergic alveolitis, Hemolytic anemia, Hepatic failure, Hepatic necrosis, Hepatitis, Pancytopenia, Seizure, Serum sickness due to drug, Stevens-Johnson syndrome, Tendon rupture, tendinitis, Thrombocytopenia, Torsades de pointes, Toxic epidermal necrolysis
Mechanism of Action
Moxifloxacin inhibits the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination.
Note
Muxava 400mg Tablets / Film-coated manufactured by AL-TAQADDOM PHARMACEUTICAL INDUSTRIES . Its generic name is Moxifloxacin. Muxava is availble in United Arab Emirates.
Farmaco UAE drug index information on Muxava Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.